Wellcome Expert Examines Need For Antibiotic Development, More Government Action

Wellcome: A lifeline for antibiotic development
Jeremy Knox, policy & advocacy lead for drug-resistant infections at Wellcome, discusses the role of governments in stimulating antibiotic development and the AMR Action Fund. Knox writes, “High on the list of acute concerns is the continuing global spread of drug-resistant infections, ‘superbugs’ which can no longer be effectively treated by existing antibiotics. … Last week’s launch of the near $1 billion industry-led AMR Action Fund marks a major and much-needed step forward in our struggle with this problem and promises to provide a shot in the arm for antibiotic development. … Long-term sustainability still depends on governments stepping in to fairly incentivize the antibiotic innovation we all need. So far, the calls for them to do so have too often gone unheeded: now it is time for politicians to recognize that, like a COVID-19 vaccine, antibiotics are a medical innovation we can’t afford to live without” (7/13).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.